AbbVie Inc. (0QCV.IL)

159,34 -2,61 (-1,61%) Alla chiusura: 07:11PM BST

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 50.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Richard A. Gonzalez	Chairman & CEO	6,95M	N/D	1954
Mr. Robert A. Michael	Pres & COO	4M	N/D	1970
Mr. Scott T. Reents	Exec. VP & CFO	2,97M	N/D	1968
Dr. Azita Saleki-Gerhardt Ph.D.	Exec. VP & COO	2,58M	N/D	1963
Mr. Jeffrey Ryan Stewart	Exec. VP & Chief Commercial Officer	2,98M	2,78M	1969
Dr. Thomas J. Hudson M.D.	Sr. VP of R&D and Chief Scientific Officer	N/D	N/D	1962
Ms. Elizabeth Shea	Sr. VP of Investor Relations	N/D	N/D	N/D
Mr. Sanjay Narayan	VP, Chief Ethics & Compliance Officer	N/D	N/D	N/D
Ms. Tracie Haas	Sr. VP of Corp. Responsibility, Brand & Communications	N/D	N/D	N/D
Mr. Timothy J. Richmond	Exec. VP & Chief HR Officer	N/D	N/D	1966

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Governance aziendale

L'ISS Governance QualityScore di AbbVie Inc. al 1 ottobre 2023 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 9; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.